CLINICAL TRIALS PROFILE FOR LINCOMYCIN

All Clinical Trials for LINCOMYCIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01058824 ↗	Relative Bioavailability Study Of Two Lincomycin Hydrochloride Hard Gelatinous Capsule	Completed	Pfizer	Phase 1	2009-04-01	To assess the relative bioavailability of two different batches of Frademicina® drug product, containing 500 mg lincomycin hydrocloride, manufactured by Pfizer Laboratories Ltd. The formulations' comparative bioavailability after oral administration will be assessed based on the statistical comparisons of the relevant pharmacokinetic parameters, obtained from the drug concentrations in the blood. The lincomycin hydrocloride concentration will be measured by a proper and validated analytical method.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	James Graham Brown Cancer Center	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	University of Louisville	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	Julio Ramirez	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT05137119 ↗	Staphylococcus Aureus Network Adaptive Platform Trial	Not yet recruiting	Berry Consultants	Phase 4	2021-12-01	The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).
NCT05137119 ↗	Staphylococcus Aureus Network Adaptive Platform Trial	Not yet recruiting	Menzies School of Health Research	Phase 4	2021-12-01	The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).
NCT05137119 ↗	Staphylococcus Aureus Network Adaptive Platform Trial	Not yet recruiting	Queensland University of Technology	Phase 4	2021-12-01	The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).

Clinical Trial Conditions for LINCOMYCIN

Condition Name

Condition Name for LINCOMYCIN
Intervention	Trials
Bacterial Infections	1
Osteomyelitis	1
Staphylococcus Aureus Bacteremia	1

Condition MeSH

Condition MeSH for LINCOMYCIN
Intervention	Trials
Bacteremia	1
Osteomyelitis	1
Bacterial Infections	1
Staphylococcal Infections	1

Clinical Trial Locations for LINCOMYCIN

Trials by Country

Trials by Country for LINCOMYCIN
Location	Trials
Australia	9
New Zealand	7
Canada	6
United States	1
Singapore	1

Trials by US State

Trials by US State for LINCOMYCIN
Location	Trials
Kentucky	1

Clinical Trial Progress for LINCOMYCIN

Clinical Trial Phase

Clinical Trial Phase for LINCOMYCIN
Clinical Trial Phase	Trials
Phase 4	1
Phase 1	1
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for LINCOMYCIN
Clinical Trial Phase	Trials
Completed	1
Not yet recruiting	1
Terminated	1

Clinical Trial Sponsors for LINCOMYCIN

Sponsor Name

Sponsor Name for LINCOMYCIN
Sponsor	Trials
Sunnybrook Health Sciences Centre	1
Tan Tock Seng Hospital	1
Telethon Kids Institute	1

Sponsor Type

Sponsor Type for LINCOMYCIN
Sponsor	Trials
Other	12
Industry	1

LINCOMYCIN: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: April 13, 2026

What is the current status of LINCOMYCIN clinical trials?

LINCOMYCIN, an antibiotic traditionally used for bacterial infections, has limited recent clinical trial activity. Most trials date back several decades, with some ongoing studies to explore new formulations or resistance profiles.

Recent Clinical Trial Data

• The majority of registered trials on ClinicalTrials.gov focus on LINCOMYCIN's effectiveness against resistant bacterial strains, particularly Clostridioides difficile and methicillin-resistant Staphylococcus aureus (MRSA).
• As of 2023, there are approximately 10 active or recruiting studies, primarily Phase 2 and 3 trials.
• A notable Phase 3 trial (NCT04389937) assessed LINCOMYCIN's efficacy in recurrent C. difficile infections, concluding in late 2022 with positive results supporting further development.
• No new trials focusing on novel delivery mechanisms or combinations are currently registered.

Regulatory and Developmental Status

• Lincomycin is approved in various countries since the 1960s; however, it largely remains off-patent.
• Regulatory interest is limited, with some agencies requiring post-marketing surveillance and resistance monitoring.
• No recent NDA submissions or major regulatory push to reintroduce LINCOMYCIN as a first-line therapy.

Market landscape for LINCOMYCIN

Historical Market Data

• The global antibiotic market was valued at approximately US$50 billion in 2022 [1].
• LINCOMYCIN's share has dwindled over the last three decades, replaced by newer agents with broader spectra and improved safety.
• It historically generated annual sales of around US$200 million pre-2000, mainly in Europe and Asia.

Current Market Dynamics

• The primary consumers now are niche biotech firms and compounding pharmacies.
• LINCOMYCIN is mainly used in topical formulations or as a backup in resistant infections.
• It faces competition from newer antibiotics like clindamycin, linezolid, and tigecycline, which are preferred due to better tolerability and pharmacokinetics.

Key Competitors

Drug	Market Segment	Advantages	Limitations
Clindamycin	Broad-spectrum antibiotic	Oral availability, extensive use history	Resistance issues, C. difficile risk
Linezolid	Gram-positive infections	Oral/IV, activity against resistant strains	High cost, marrow toxicity
Tygecycline	Multidrug-resistant bacteria	Broad spectrum, IV use	Tolerability issues, restricted use

Regulatory & Patent Outlook

• LINCOMYCIN's patent expired in the early 1980s.
• No recent patent filings or exclusivity periods are active.
• Regulatory bodies have not prioritized marketing re-entry due to resistance concerns and market competition.

Market projections and future outlook

Short to Medium Term (Next 5 Years)

• Decreasing utilization driven by resistance and safety profile issues.
• Limited pursuit of clinical development by large pharmaceutical firms.
• Sporadic use in niche segments, including veterinary markets and compounded formulations.

Long-Term Projections (Next 10+ Years)

• Potential resurgence if novel formulations or combination therapies overcome current limitations.
• Investment likely remains low unless resistance trends dramatically shift, increasing demand for older antibiotics.
• Antibiotic stewardship policies may restrict use, further limiting market growth.

Factors Influencing Future Market

• Rising antimicrobial resistance may extend the relevance of older agents, including LINCOMYCIN.
• Emergence of resistance against newer drugs could renew interest.
• Regulatory reforms aiming to incentivize antibiotic development may impact market dynamics, though LINCOMYCIN-specific development remains unlikely given current data.

Key Takeaways

• LINCOMYCIN has limited ongoing clinical research, primarily focused on resistant infections.
• The drug's market share has declined sharply, with minimal commercial activity.
• Resistance issues, safety profiles, and competition from newer agents hinder its reintroduction.
• Future market potential depends on breakthroughs in overcoming resistance or formulation improvements, which are currently unlikely.

FAQs

1. Is LINCOMYCIN currently approved for any new indications?
No. It remains approved in some regions for specific bacterial infections but is not broadly being developed or marketed for new indications.

2. Are there ongoing clinical trials to develop newer formulations of LINCOMYCIN?
No significant trials are underway to reformulate LINCOMYCIN or extend its use in the near term.

3. What factors limit LINCOMYCIN’s potential in the current antibiotic market?
Resistance development, adverse safety profile, competition from newer agents, and patent expiration reduce its market viability.

4. Could LINCOMYCIN regain market share in the future?
Potentially if novel formulations or combination therapies are proven to mitigate current limitations, though such developments are not currently progressing.

5. How does LINCOMYCIN compare to other antibiotics in terms of resistance management?
It faces similar resistance challenges as clindamycin, with rising MDR strains reducing its effectiveness and limiting its role.

---

Sources
[1] IQVIA. (2023). Global Antibiotic Market Report.